)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Mereo Biopharma Group
Mereo Biopharma Group (MREO) investor relations material
Mereo Biopharma Group Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary9 Nov, 2026
Executive summary
Q3 revenue was $0.8m from the Sentynl alvelestat option fee; net loss narrowed to $5.9m from $7.0m YoY as operating expenses declined.
Cash was $26.1m at September 30, 2026, and current plans project funding into late 2027; additional funding or cash conservation may be needed longer term.
Financial highlights
Q3 revenue was $0.8m versus none in Q3 2025; 9M revenue was $0.8m versus $0.5m, including a one-time ReproNovo milestone in 2025.
Q3 R&D was $2.1m versus $4.3m and G&A was $4.9m versus $6.0m; 9M R&D was $8.6m versus $13.6m and G&A was $14.2m versus $18.8m.
Q3 net loss was $5.9m versus $7.0m; 9M net loss was $19.6m versus $34.5m and operating loss was $22.0m versus $31.7m.
Cash and cash equivalents were $26.1m at September 30, 2026, versus $41.0m at December 31, 2025.
Outlook and guidance
Current cash is expected to fund committed clinical trials, operating expenses and capital requirements into late 2027; estimates exclude potential business-development payments and may require additional funding or cash conservation.
Alvelestat Phase 3 initiation is targeted for early 2027; study design is being refined with Sentynl and the FDA, with an update based on FDA interactions expected before year-end 2026.
Setrusumab regulatory discussions with Ultragenyx are assessing data needed for a filing and whether a pediatric OI path forward exists; significant operating losses are expected as development continues.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Mereo Biopharma Group
- Setrusumab misses Phase 3 fracture endpoints; alvelestat planning and late-2027 runway continue.MREO
Corporate presentation - Major regulatory updates and new data for rare disease programs expected within the next quarter.MREO12th Annual Cantor Fitzgerald Global Healthcare Conference
- Net loss narrowed, cash runway extends into late 2027, and a major licensing deal was signed.MREOQ2 2026
- Setrusumab and alvelestat advance in late-stage development, with key regulatory and partnership milestones ahead.MREOJefferies Global Healthcare Conference 2026
- Q1 2026 net loss improved to $6.7M; cash runway into mid-2027 as pipeline advances.MREOQ1 2026
- Shareholders will vote on key governance, compensation, and capital flexibility proposals at the AGM.MREOProxy filing
- Board recommends FOR all AGM proposals, including share issuance authority and director re-elections.MREOProxy filing
- Net loss narrowed in 2025 as rare disease pipeline advanced and cash runway extended to mid-2027.MREOQ4 2025
- Setrusumab nears pivotal data in OI, with strong commercial and regulatory positioning in Europe.MREOJefferies 2024 Global Healthcare Conference
Next Mereo Biopharma Group earnings date
Q4 202619 Mar, 2027
Mereo Biopharma Group
Next Mereo Biopharma Group earnings date
Q4 202619 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Mereo Biopharma Group plc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare diseases and oncology. The company has a diverse portfolio of product candidates in various stages of clinical development, including treatments for conditions such as osteogenesis imperfecta, Alpha-1 anti-trypsin deficiency, and different types of cancer. Among its leading candidates are etigilimab, an antibody designed for tumor treatment, and alvelestat, intended for Alpha-1 anti-trypsin deficiency. Founded in 2015, Mereo Biopharma Group plc is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.